A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.
Condition or disease
Prostatic NeoplasmsNeoplasm MetastasisPalliative Care
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
diagnosis of prostate cancer
receiving docetaxel-based chemotherapy at the CCI
age 18 years or over
approval of oncologist
informed written consent
life expectancy less than 6 months
Karnofsky performance score less than 70
contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
unable to understand, read, write and speak English
unable or unwilling to attend supervised exercise sessions 3 times weekly
unable or unwilling to complete outcome assessments